SpinalCyte received a new Australian patent related to its fibroblast technology.
Here are three things to know:
1. CybroCell now comprises 36 U.S. and foreign issued patents with 40 pending.
2. The new patent involves differentiating human dermal fibroblast into chondrocyte-like cells by exposing them to a specific environment of growth factors, hypoxia, hydrostatic pressure and shear stress.
3. CybroCell is an off-the-shelf allogenic human dermal fibroblast product designed to treat degenerative disc disease.